Thymosin Alpha-1 vs VIP
Both Thymosin Alpha-1 and VIP are used for anti-inflammatory. Here's how their evidence, dosing, and regulatory status actually compare.
Thymosin Alpha-1
Evidence AThymosin Alpha-1 (Tα1)
A 28-amino-acid thymic peptide that matures and modulates T-cells. Used internationally as an adjunct in hepatitis, sepsis, and immune-compromised cancer care.
View full Thymosin Alpha-1 profile →VIP
Evidence BVasoactive Intestinal Peptide
A 28-amino-acid neuropeptide with broad immunomodulatory effects. Used clinically (intranasal) by some practitioners for chronic inflammatory response syndrome (CIRS).
View full VIP profile →Side-by-Side
| Attribute | Thymosin Alpha-1 | VIP |
|---|---|---|
| Evidence Grade | A | B |
| FDA Status | Approved in 35+ countries for hepatitis B/C, immune support; not FDA-approved in US (orphan-drug designations) | Not FDA-approved — investigational; ongoing trials for sarcoidosis |
| Typical Dose | 1.6 mg twice weekly (subcutaneous) | 50 mcg intranasal, 4 times daily (CIRS protocols) |
| Clinics Indexed | 192 | 24 |
| Categories | immune, anti-inflammatory | anti-inflammatory, neuroprotection |
Key reported benefits — Thymosin Alpha-1
- ✓T-cell maturation
- ✓Antiviral immunity
- ✓Tumor immune support
- ✓Sepsis adjunct
Key reported benefits — VIP
- ✓Anti-inflammation
- ✓Pulmonary effects
- ✓Neuroprotection
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.